T7503

Upadacitinib (ABT-494) (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.

Ubiquitination-IN-2 is a potent inhibitor of E1-E2 protein−protein interactions (PPI), exhibiting inhibitory activity with a dissociation constant (Kd) of 0.72 μM for the ubiquitin E1 (Uba1) enzyme. By blocking the transfer of ubiquitin from E1 to E2, Ubiquitination-IN-2 serves as a valuable tool in cancer research [1].

Pirnabine, a cannabinoid receptor ligand, is utilized in glaucoma research [1].

2'-Chloro-N6-(3-trifluoromethyl)benzyl adenosine, a purine nucleoside analog, exhibits broad antitumor activity, particularly against indolent lymphoid malignancies. Its anticancer mechanisms include inhibition of DNA synthesis and induction of apoptosis, among others [1].

Upadacitinib is a potent and selective JAK inhibitor. Upadacitinib is approximately 74 fold selective for Jak1 over Jak2 in cellular assays dependent on specific, relevant cytokines. Upadacitinib demonstrates efficacy in rat arthritis models.